G. Baciarello
Azienda Ospedaliera San Camillo-Forlanini(IT)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Cancer Diagnosis and Treatment, Cancer Treatment and Pharmacology, Cancer, Lipids, and Metabolism
Most-Cited Works
- → A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)(2019)243 cited
- → Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(2022)181 cited
- → Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL(2015)115 cited
- → Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre(2018)90 cited
- → Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I–II)(2010)22 cited
- → Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy(2018)14 cited
- → Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): The Gustave Roussy experience(2017)12 cited
- → Etoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phase III).(2011)8 cited
- Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.(2015)
- → Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors(2024)4 cited